What if up to 80% of high-risk DCIS patients could avoid unnecessary underarm surgery?

The opportunity to avoid surgery

The current treatment standard

Every year, hundreds of thousands of women across the world are diagnosed with a non-invasive or pre-invasive breast cancer called ductal carcinoma in situ (DCIS).

The standard treatment for high-risk DCIS is to remove the DCIS in the breast, and at the same time, perform surgery near the armpit to remove a small number of lymph nodes, known as a sentinel lymph node biopsy (SLNB).

The SLNB procedure helps surgeons discover whether any of the cancer has begun to spread, which in turn helps understand the best course of treatment going forward.

But could less treatment be better?

In pioneering clinicial studies, published data is beginning to suggest that it may be possible for up to 80% of high-risk patients to avoid this surgical procedure altogether.

The way forward involves a treatment involving the Magtrace© lymphatic tracer from Endomag (exclusively supplied by Mammotome in North America) and a new technique called delayed sentinel lymph node biopsy (dSLNB)†.

It's time to #SaveOurNodes.

I want this

Trusted by surgeons and patients

Find out why an ever-growing number of physicians across the US are delighted to offer their patients the ‘Delayed' sentinel lymph node biopsy (dSLNB) technique.

See more from surgeons

Information for your surgeon

For more information on the technique for both you and your surgeon, download our 'Delayed' SLNB patient information documents.

Clinical information

Clinical research is currently underway in the United States and in Sweden, with more countries and hospitals seeing the technique's benefits.

Read the Swedish study findings Read the UH Hospitals findings See Magtrace's extensive clinical data

Supported by